(“Belluscura” or “Company”)
Exercise of Warrants and Total Voting Rights
LONDON, U.K. AND PLANO, TX, U.S. (29 November 2021). Belluscura plc (AIM: BELL), a leading medical device developer focused on lightweight and portable oxygen enrichment technology, announces that it has received notification from a warrant holder to exercise warrants over 179,537 shares in the share capital of Belluscura (“the Warrant Shares”) at exercise prices of 13 pence (139,537 shares) and 15 pence (40,000 shares). The consideration for the exercise of the Warrant Shares amounts, in aggregate, to a cash value of £24,139.81.
The Warrant Shares were allotted on 26 November 2021. Application has been made for the Warrant Shares to be admitted to trading on AIM (“Admission”), and Admission is expected to be on or around 2 December 2021. These shares will rank pari passu with the ordinary shares of the Company in the issue.
Total voting rights
The Company’s total issued capital, after the issue of the Warrant Shares, will be 113,486,938 ordinary shares. As the Company does not hold any shares in Treasury, this figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company following Admission.
Belluscura plc www.belluscura.com
Robert Rauker, Chief Executive Officer via Walbrook PR
Anthony Dyer, Chief Financial Officer
SPARK Advisory Partners Ltd (NOMAD) Tel: +44 (0)20 3368 3550
Dowgate Capital Ltd (Broker & Bookrunner) Tel: +44 (0)20 3903 7715
James Serjeant / Nicholas Chambers
Walbrook PR Ltd (Media & Investor Relations) Tel: +44 (0)20 7933 8780 or firstname.lastname@example.org
Paul McManus / Sam Allen Mob: +44 (0)7980 541 893 / +44 (0)7502 558 258